Japan Nonalcoholic Steatohepatitis Therapeutics Market (2025-2031) | Analysis, Size & Revenue, Value, Share, Growth, Forecast, Outlook, Industry, Segmentation, Competitive Landscape, Trends, Companies

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 Japan Country Macro Economic Indicators

3.2 Japan Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, 2021 & 2031F

3.3 Japan Nonalcoholic Steatohepatitis Therapeutics Market - Industry Life Cycle

3.4 Japan Nonalcoholic Steatohepatitis Therapeutics Market - Porter's Five Forces

3.5 Japan Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume Share, By Drug Type, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of nonalcoholic steatohepatitis (NASH) in Japan

4.2.2 Growing awareness about NASH and its associated risks

4.2.3 Technological advancements in NASH therapeutics

4.3 Market Restraints

4.3.1 High cost of NASH therapeutics

4.3.2 Limited reimbursement policies for NASH treatments

4.3.3 Stringent regulatory requirements for NASH drug approvals

6.1 Japan Nonalcoholic Steatohepatitis Therapeutics Market, By Drug Type

6.1.1 Overview and Analysis

6.1.2 Japan Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Drug Type, 2021- 2031F

6.1.3 Japan Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Obeticholic Acid (OCA), 2021- 2031F

6.1.4 Japan Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Aramchol (Arachidyl Amido Cholanoic Acid), 2021- 2031F

6.1.5 Japan Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Saroglitazar, 2021- 2031F

6.1.6 Japan Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Elafibranor, 2021- 2031F

7.1 Japan Nonalcoholic Steatohepatitis Therapeutics Market Export to Major Countries

7.2 Japan Nonalcoholic Steatohepatitis Therapeutics Market Imports from Major Countries

8.1 Number of clinical trials for NASH therapeutics in Japan

8.2 Adoption rate of new NASH treatment guidelines by healthcare providers

8.3 Patient adherence to NASH treatment regimens

8.4 Number of research collaborations between pharmaceutical companies and academic institutions in Japan to develop NASH therapies

8.5 Average time taken for regulatory approval of NASH drugs in Japan

9.1 Japan Nonalcoholic Steatohepatitis Therapeutics Market Opportunity Assessment, By Drug Type, 2021 & 2031F

10.1 Japan Nonalcoholic Steatohepatitis Therapeutics Market Revenue Share, By Companies, 2024

10.2 Japan Nonalcoholic Steatohepatitis Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters